These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24318486)

  • 61. Algorithm evolution for drug resistance prediction: comparison of systems for HIV-1 genotyping.
    Wagner S; Kurz M; Klimkait T;
    Antivir Ther; 2015; 20(6):661-5. PubMed ID: 25710167
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya.
    Koigi P; Ngayo MO; Khamadi S; Ngugi C; Nyamache AK
    BMC Res Notes; 2014 Dec; 7():890. PubMed ID: 25487529
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antiretroviral drug resistance among antiretroviral-naïve and treatment experienced patients infected with HIV in Iran.
    Baesi K; Ravanshad M; Ghanbarisafari M; Saberfar E; Seyedalinaghi S; Volk JE
    J Med Virol; 2014 Jul; 86(7):1093-8. PubMed ID: 24740443
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa.
    Villabona-Arenas CJ; Vidal N; Guichet E; Serrano L; Delaporte E; Gascuel O; Peeters M
    AIDS; 2016 Nov; 30(17):2577-2589. PubMed ID: 27603287
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana.
    Martin-Odoom A; Brown CA; Odoom JK; Bonney EY; Ntim NAA; Delgado E; Lartey M; Sagoe KW; Adiku T; Ampofo WK
    Virol J; 2018 Sep; 15(1):143. PubMed ID: 30223845
    [TBL] [Abstract][Full Text] [Related]  

  • 66. HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya.
    Kantor R; DeLong A; Balamane M; Schreier L; Lloyd RM; Injera W; Kamle L; Mambo F; Muyonga S; Katzenstein D; Hogan J; Buziba N; Diero L
    J Int AIDS Soc; 2014; 17(1):19262. PubMed ID: 25413893
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Frequency of HIV-1 Infection in Iranian Children and Determination of the Transmitted Drug Resistance in Treatment-Naïve Children.
    Jarchi M; Bokharaei-Salim F; Esghaei M; Kiani SJ; Jahanbakhsh F; Monavari SH; Ataei-Pirkooh A; Marjani A; Keyvani H
    Curr HIV Res; 2019; 17(6):397-407. PubMed ID: 31702525
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Determinants of virological failure and antiretroviral drug resistance in Mozambique.
    Rupérez M; Pou C; Maculuve S; Cedeño S; Luis L; Rodríguez J; Letang E; Moltó J; Macete E; Clotet B; Alonso P; Menéndez C; Naniche D; Paredes R
    J Antimicrob Chemother; 2015 Sep; 70(9):2639-47. PubMed ID: 26084302
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.
    Soulie C; Grudé M; Descamps D; Amiel C; Morand-Joubert L; Raymond S; Pallier C; Bellecave P; Reigadas S; Trabaud MA; Delaugerre C; Montes B; Barin F; Ferré V; Jeulin H; Alloui C; Yerly S; Signori-Schmuck A; Guigon A; Fafi-Kremer S; Haïm-Boukobza S; Mirand A; Maillard A; Vallet S; Roussel C; Assoumou L; Calvez V; Flandre P; Marcelin AG;
    J Antimicrob Chemother; 2017 Aug; 72(8):2351-2354. PubMed ID: 28472307
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Frequency of primary resistance to antiretroviral drugs and genetic variability of HIV-1 among infected pregnant women recently diagnosed in Luanda-Angola.
    Castelbranco EP; da Silva Souza E; Cavalcanti AM; Martins AN; de Alencar LC; Tanuri A
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1313-6. PubMed ID: 20929349
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Performance characteristics of Allele-Specific PCR (ASPCR) in detecting drug resistance mutations among non-B HIV-1 Variants.
    Adawaye C; Fokam J; Kamangu EN; Ngwese DTA; Susin F; Moussa AM; Hig-Zounet B; Mad-Toingué J; Tidjani A; Vaira D; Moutschen M
    J Virol Methods; 2024 Jan; 323():114856. PubMed ID: 38000668
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Genetic diversity and drug resistance of HIV-1 among infected pregnant women newly diagnosed in Luanda, Angola.
    Sebastião CS; Neto Z; de Jesus CS; Mirandela M; Jandondo D; Couto-Fernandez JC; Tanuri A; Morais J; Brito M
    PLoS One; 2019; 14(11):e0225251. PubMed ID: 31770425
    [TBL] [Abstract][Full Text] [Related]  

  • 73. HIV-1 Genetic Diversity and Drug Resistance Mutations Among Treatment-Naive Adult Patients in Suriname.
    Abdoel Wahid F; Sno R; Darcissac E; Lavergne A; Adhin MR; Lacoste V
    AIDS Res Hum Retroviruses; 2016 Dec; 32(12):1223-1228. PubMed ID: 27412696
    [TBL] [Abstract][Full Text] [Related]  

  • 74. HIV-1 drug mutations in children from northern Tanzania.
    Shao ER; Kifaro EG; Chilumba IB; Nyombi BM; Moyo S; Gaseitsiwe S; Musonda R; Johannessen A; Kibiki G; Essex M
    J Antimicrob Chemother; 2014 Jul; 69(7):1928-32. PubMed ID: 24729604
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An Alarmingly High Proportion of HIV-1 Isolates Carrying Mutations Corresponding to Resistance to Antiretroviral Drugs among HIV-Positive High-Risk Groups in Central Vietnam: a Substudy of the National Sentinel Survey.
    Do HT; Nguyen DT; Nguyen LAT; Do DH; Le HX; Trinh XMT; Ton HVN; Sawada I; Kitamura N; Le MN; Yoshihara K; Phan THT; Bui CT; Ariyoshi K; Yoshida LM
    Jpn J Infect Dis; 2017 Nov; 70(6):621-627. PubMed ID: 28890504
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The evolution of HIV-1 group M genetic variability in Southern Cameroon is characterized by several emerging recombinant forms of CRF02_AG and viruses with drug resistance mutations.
    Agyingi L; Mayr LM; Kinge T; Orock GE; Ngai J; Asaah B; Mpoame M; Hewlett I; Nyambi P
    J Med Virol; 2014 Mar; 86(3):385-93. PubMed ID: 24248638
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HIV Drug Resistance Testing in a Resource Limited Setting with High Viral Diversity: The First Twenty Eight Months Experience.
    Ngo-Malabo ET; Ngoupo PA; Sadeuh-Mba SA; Akongnwi E; Banaï R; Ngono L; Bilong-Bilong CF; Kfutwah A; Njouom R
    Curr HIV Res; 2017; 15(4):297-305. PubMed ID: 28745207
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ultradeep sequencing in the therapeutic management of HIV-1 infection at treatment initiation.
    Todesco E; Mercier-Darty M; Jung M; Bottero J; Boyd A; Marcelin AG; Calvez V; Morand-Joubert L
    J Antimicrob Chemother; 2015; 70(6):1919-20. PubMed ID: 25637517
    [No Abstract]   [Full Text] [Related]  

  • 79. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun.
    Vessière A; Rousset D; Kfutwah A; Leoz M; Depatureaux A; Simon F; Plantier JC
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):107-10. PubMed ID: 19770803
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.
    Metzner KJ; Rauch P; Braun P; Knechten H; Ehret R; Korn K; Kaiser R; Sichtig N; Ranneberg B; van Lunzen J; Walter H
    J Clin Virol; 2011 Feb; 50(2):156-61. PubMed ID: 21056001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.